Jefferies, Goldman Sachs: Advisory on $627M GTCR Acquisition Explained

Jefferies and Goldman Sachs are advising on GTCR’s $627 million acquisition of Surmodics.

Surmodics, a leading provider of surface modification technologies for medical devices and chemical components for in vitro diagnostics. This deal offers Surmodics’ shareholders a substantial premium, reflecting the company’s achievements and progress. Surmodics President and CEO Gary Maharaj emphasized that GTCR is an ideal partner due to its extensive healthcare sector expertise.

GTCR will acquire all outstanding shares of Surmodics for $43.00 per